Domestic launch process and current situation of Sotoraxibu

Sotorasib (Sotorasib), as a targeted treatment drug for KRAS G12C mutation, has attracted widespread attention around the world since it received accelerated approval from the FDA in the United States in 2021. KRAS G12C mutation is one of the most common driver genes in lung cancer, and the emergence of sotorasiib provides these patients with a new treatment option. Its unique mechanism of action allows the drug to accurately target the mutated gene, thereby inhibiting the growth and spread of tumor cells, demonstrating significant therapeutic effects.

As of now, although sotorasibu has been widely recognized internationally, it has not yet been approved for marketing by the National Medical Products Administration (NMPA) in my country. This means that domestic patients cannot directly purchase this innovative drug in domestic pharmacies. However, domestic clinical trials of sotorasibu are ongoing. It is expected that in the next few years, it will complete all necessary approval procedures and officially enter the Chinese market, bringing new treatment hope to Chinese patients.

Although sotoracib is not yet available in China, domestic patients can still purchase the drug. In addition, participating in ongoing clinical trials in China is also an effective way to obtain sotorasiib. This not only provides valuable treatment opportunities for patients, but also provides important evaluation data for the safety and effectiveness of new drugs.

In overseas markets, the supply situation of Sotoraxibu is diversified. There are original versions from Hong Kong, Europe and other regions, as well as generic versions produced by pharmaceutical factories such as Lucius, Big Bear, Everest of Bangladesh, and Element Laos. These generic drugs are more affordable and provide more choices for patients with limited financial conditions. However, patients must be extremely cautious when choosing generic drugs to ensure that the source of the drugs is reliable and the quality is guaranteed to avoid risks caused by drug quality issues.

In short, sotorasiib, as an innovative drug targetingKRAS G12C mutation, has demonstrated remarkable therapeutic efficacy and safety around the world. Although domestic patients are currently unable to obtain this drug directly through formal channels, with the advancement of the drug review and approval process and the in-depth clinical trials, Chinese patients are expected to see sotorasibu on the market in the near future.